澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PROTEOMICS INTERNATIONAL LAB

0.140

0.000

成交量：9.57萬

成交額：1.34萬

市值：2,311.63萬

市盈率：-2.69

高：0.145

開：0.145

低：0.140

收：0.140

52周最高：0.860

52周最低：0.098

股本：1.65億

流通股本：1.22億

量比：0.95

換手率：0.08%

股息：- -

股息率：- -

每股收益(TTM):-0.052

每股收益(LYR):-0.064

淨資產收益率：-92.99%

總資產收益率：-46.46%

市淨率：3.98

市盈率(LYR):-2.20

資料載入中...

總覽公司新聞公告

概念

醫藥生物股-1.73%

資金流向

資金流入：

資金流出：

新聞

Proteomics International Laboratories — 本財務期間未支付、建議或宣派任何股息

Proteomics International Laboratories 與 Healius 簽署 Promarker 產品組合全國分銷協議

PROTEOMICS INTERNATIONAL LAB獲美國專利授予，革新子宮內膜異位症診斷檢測

Proteomics International Laboratories宣佈重組、高管任命及董事會變動

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/PIQ.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PIQ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PIQ.AU\",,,,,undefined,":{"symbol":"PIQ.AU","market":"AU","secType":"STK","nameCN":"PROTEOMICS INTERNATIONAL LAB","latestPrice":0.14,"timestamp":1789107120000,"preClose":0.14,"halted":0,"volume":95692,"delay":0,"changeRate":0,"nameEN":"PROTEOMICS INTERNATIONAL LAB","floatShares":121549097,"shares":165116433,"eps":-0.0521,"marketStatus":"休市中","change":0,"latestTime":"09-11 16:12:00 AEST","open":0.145,"high":0.145,"low":0.14,"amount":13435,"amplitude":0.035714,"askPrice":0.15,"askSize":98000,"bidPrice":0.14,"bidSize":46687,"shortable":3,"etf":0,"ttmEps":-0.0521,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.14,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.9476012904261119,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PIQ.AU","preClose":0.14,"auctionPrice":0.14,"auctionVolume":180,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106941673}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PIQ.AU\",,,,,undefined,":{"symbol":"PIQ.AU","floatShares":121549097,"roa":"-46.46%","roe":"-92.99%","lyrEps":-0.063752,"volumeRatio":0.9476012904261119,"shares":165116433,"dividePrice":0,"high":0.145,"amplitude":0.035714,"preClose":0.14,"low":0.14,"week52Low":0.098,"pbRate":"3.98","psRate":"6.86","week52High":0.86,"institutionHeld":0,"latestPrice":0.14,"committee":-0.354648,"eps":-0.0521,"divideRate":0,"volume":95692,"delay":0,"ttmEps":-0.0521,"open":0.145,"prevYearClose":0.655,"prevWeekClose":0.15,"prevMonthClose":0.15,"prevQuarterClose":0.115,"fiveDayClose":0.15,"twentyDayClose":0.162,"sixtyDayClose":0.115},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PIQ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PIQ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PIQ.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151806519","title":"Proteomics International Laboratories — 本財務期間未支付、建議或宣派任何股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1151806519","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151806519?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 14:42","pubTimestamp":1788158524,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories——在当前财务期间，公司既未支付、亦未建议或宣派任何股息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7048","PIQ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191921589","title":"Proteomics International Laboratories 與 Healius 簽署 Promarker 產品組合全國分銷協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1191921589","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191921589?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 06:31","pubTimestamp":1784673073,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories 已与 Healius 就其 Promarker 产品组合签署了一份全国分销协议。此举旨在扩大其创新诊断解决方案的市场覆盖范围，通过 Healius 广泛的网络，将 Promarker 产品带给更广泛的医疗专业人士和患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","PIQ.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166630655","title":"PROTEOMICS INTERNATIONAL LAB獲美國專利授予，革新子宮內膜異位症診斷檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=1166630655","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166630655?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 08:12","pubTimestamp":1783469559,"startTime":"0","endTime":"0","summary":"PROTEOMICS INTERNATIONAL LAB成功获得一项美国专利授权，该专利涉及其在子宫内膜异位症领域的一项创新诊断检测技术。这一进展标志着公司在生物标志物发现和诊断解决方案方面的专业能力获得了重要认可，有望为其在医疗诊断市场的布局提供新的知识产权保护与竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7048","PIQ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142422629","title":"Proteomics International Laboratories宣佈重組、高管任命及董事會變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1142422629","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142422629?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 09:45","pubTimestamp":1776390315,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories有限公司公布重大运营调整，包括组织架构重组、高层人事任命及董事会更新。\n公司已正式任命Tim Luscombe担任首席财务官，这一关键人事变动将强化其财务管理团队。与此同时，为提升运营效率，公司决定削减25%的岗位编制。此项精简措施预计将实现每年超过100万澳元的常态化成本节约。\n此次人员调整是公司整体运营重组计划的重要组成部分。Proteomics International Laboratories表示，通过重构业务架构，旨在优化资源配置，提升长期竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","PIQ.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PIQ.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.017262}]}}